Veracyte (VCYT) Tops Q2 EPS by 2c, Amends Agreement with Sanofi's Genzyme
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
Veracyte (VCYT) PT, Estimates Bumped at Piper Jaffray Despite Q2 Rev Miss
August 14, 2014 6:57 AM EDTPiper Jaffray analyst William Quirk reiterated an Overweight rating while bumping estimates and his price target on Veracyte, Inc (NASDAQ: VCYT) following Q2 results and the related after hours sell-off on the revenue miss.
Quirk comments, "Veracyte reported a 71.2% yoy revenue increase... More
